Key result
Pembrolizumab treatment resulted in stable disease in a patient with primary pleural epithelioid angiosarcoma after 13 cycles of therapy.
Why the study?
Primary pleural angiosarcoma is an extremely rare malignancy with no consensus on treatment, and its clinical course is usually quickly fatal regardless of therapy.
Case Report (n=1)
No
Anti-PD-1 therapy with pembrolizumab may provide a viable treatment option for patients with primary pleural angiosarcoma.
Answers are grounded in this paper and cite their sources.
May support pembrolizumab in primary pleural angiosarcoma; hypothesis-generating and requires prospective validation before practice change.
RATIONALE: Primary pleural angiosarcoma (PPA) is an extremely rare malignancy for which there is no consensus on treatment. The clinical course of PPA is usually quickly fatal, regardless of the treatment used. PATIENT CONCERNS: We describe the rare case of a 52-year-old man who presented initially with hemoptysis and received emergency surgery for the primary. DIAGNOSES: He received a confirmed diagnosis of primary pleural angiosarcoma (PPA) by postoperative pathology and was subsequently treated with radiotherapy and chemotherapy, but had failed and was intolerant to chemotherapy. INTERVENTIONS: The patient had 5% tumor PD-L1 positivity with 22C3 pharmDx and received pembrolizumab (200 mg every 21 days) for 13 cycles. OUTCOMES: The disease remained well controlled according to the RECIST 1.1. criteria. He is currently under observation and waiting to start the next cycle of immunotherapy. LESSON: Our case report suggests that the use of anti-PD-1 therapy does show efficacy in the treatment of PPA and may provide a viable treatment option for patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a case report in Primary pleural epithelioid angiosarcoma (n=1). Pembrolizumab was evaluated on Tumor response according to RECIST 1.1 criteria. Pembrolizumab treatment resulted in stable disease in a patient with primary pleural epithelioid angiosarcoma after 13 cycles of therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: